MDxHealth (NASDAQ:MDXH – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.
Institutional and Insider Ownership
10.5% of Precipio shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 16.9% of Precipio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
MDxHealth has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $90.05 million | 1.72 | -$38.07 million | ($0.64) | -5.11 |
| Precipio | $18.53 million | 2.18 | -$4.29 million | ($0.82) | -28.16 |
Precipio has lower revenue, but higher earnings than MDxHealth. Precipio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for MDxHealth and Precipio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
MDxHealth currently has a consensus target price of $7.75, indicating a potential upside of 137.00%. Given MDxHealth’s stronger consensus rating and higher probable upside, equities research analysts clearly believe MDxHealth is more favorable than Precipio.
Profitability
This table compares MDxHealth and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -30.50% | -1,078.01% | -20.05% |
| Precipio | -5.50% | -10.07% | -6.71% |
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
